The future of

prostate cancer treatment


SpectraCure is developing a future system for treatment of prostate cancer. Our ambition is to offer patients with recurrent prostate cancer an effective treatment with few side effects while maintaining a high quality of life.

SpectraCures system is suitable for treating internal solid tumours, and as a first indication, the system has been adapted for treating recurrent prostate cancer. Treatment of recurrent prostate cancer after radiation therapy is controversial due to the high rates of severe side effects; this is exactly why SpectraCure has chosen to focus on recurrent prostate cancer.

Our method is based on photodynamic therapy (PDT), where the use of a medication makes the tissue sensitive to light. The medication is then activated by laser light, which eliminates the cancer cells.

We are currently running a clinical study for patients with recurrent prostate cancer at leading hospitals in the United States, the United Kingdom, Canada, and Sweden. The study objectives are to determine the most effective medication and light dose, and to evaluate the treatment effect.

“…SpectraCure represents the future of personalized PDT in prostate cancer treatment…”
Brian Wilson, Senior Scientist på Princess Margaret Cancer Center och professor vid University of Toronto, Department of Medical Biophysics

New treatment of prostate cancer

Recurrent prostate cancer after radiation therapy can be difficult to treat, and available treatments often result in side effects that affect the patient’s quality of life. Therefore, SpectraCure has chosen recurrent prostate cancer as the first prioritised indication with the goal to eventually offer patients with recurrent prostate cancer a local treatment with few side effects.

The treatment method, interstitial PDT, is enabled by an entirely new generation of treatment system that includes a software for dose planning and a laser unit. The integrated IDOSE® software calculates and adapts the laser exposure for each patient. The dose planning is important because overexposure to laser light may lead to damage to healthy tissue. In turn, underexposure can lead to incomplete treatment and recurrence of the tumour after treatment.

Our vision

For a tomorrow where we cure cancer and improve quality of life for those affected


Why invest in SpectraCure?

Global market with high growth

The global prostate cancer market is growing and is estimated to be worth USD 100 billion by 2026. More and more men are affected due to increased life expectancy.

A real clinical need

Today, the treatment of recurrent prostate cancer is controversial due to the severe side effects associated with several treatment options. Recurrent prostate cancer is our first prioritised indication.

A new treatment option  

Our treatment method has the potential to become a beneficial alternative to other treatments, such as hormone therapy. Our method has the potential to cause fewer side effects and offer an improved quality of life.

Health economic viability

Our treatment method is designed to be less resource-consuming since our treatment is performed in a single session, allowing the patient to go home the same day.

Attractive business model with continuous revenue streams

The system is placed at the customer’s site for a low cost, providing a reduced barrier to entry. Recurring revenue is generated through the sale of sterile disposable equipment, with customers paying per treatment.

Potential to develop treatment for more cancer diagnoses

The treatment system has the potential to be suitable for treating several types of internal solid tumours, such as breast cancer.

This website uses cookies

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.